Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H7Cl2NO |
Molecular Weight | 228.075 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=C(C=C1)C(Cl)=CC(Cl)=C2O
InChI
InChIKey=GPTXWRGISTZRIO-UHFFFAOYSA-N
InChI=1S/C10H7Cl2NO/c1-5-2-3-6-7(11)4-8(12)10(14)9(6)13-5/h2-4,14H,1H3
DescriptionCurator's Comment: Description is created based on several sources, including http://www.sciencedirect.com/science/article/pii/S0022202X15488141 and http://www.ncbi.nlm.nih.gov/pubmed/140848
Curator's Comment: Description is created based on several sources, including http://www.sciencedirect.com/science/article/pii/S0022202X15488141 and http://www.ncbi.nlm.nih.gov/pubmed/140848
Chlorquinaldol is a halogenated hydroxyquinoline with properties similar to those of clioquinol. It is mainly applied topically in infected skin conditions and in vaginal infections. The product is applied for local treatment of cortico-sensitive dermatosis with moderately manifested superinfection, acute and subacute eczema, dermatitis, pyodermia, intertrigo, infected wounds, dermatomycosis, pemphigus in newborn. Chlorquinaldol is also used as antiseptic, fungistat, or deodorant. Chlorquinaldol is not commercially available in the U.S. but is used in other countries principally as an amebicide for nonspecific diarrheas and gynecologic infections. It is known most commonly under the proprietary name of Sterosan. Other trade names include Cynotherax, Gyno-Sterosan, Saprosan, Siogeno, Siosteran, Slosteran and Steroxin.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/6236746 |
|||
Target ID: CHEMBL5192 Sources: http://www.ncbi.nlm.nih.gov/pubmed/24387280 |
10.1 µM [IC50] | ||
Target ID: Mycobacterium tuberculosis growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=17178795 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Chlorquinaldol Approved UseChlorquinaldol is primarily indicated in conditions like skin infections, vaginal infections. Launch Date2007 |
|||
Curative | Gynosan Vaginal Pessary Approved UseGynosan Vaginal Pessary is used in the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: skin infections, vaginal infections |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.sopharma.com/chlorquinaldol-h.php
Applied in a thin layer on affected skin areas 1-3 times daily. Therapy duration is up to 8 days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6236746
Chlorquinaldol displayed enhanced E. coli 205 bactericidal activity in human duodeno-pancreatic secretions with MIC 0.5ug/ml
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
D08AH02
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
||
|
WHO-ATC |
P01AA04
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
||
|
WHO-VATC |
QG01AC03
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
||
|
NDF-RT |
N0000185508
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
||
|
WHO-ATC |
G01AC03
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
||
|
WHO-ATC |
R02AA11
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
||
|
WHO-VATC |
QR02AA11
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
||
|
WHO-VATC |
QD08AH02
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
755830
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
2407
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
C77042
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
6301
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
m3466
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
N0000175629
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | Increased Histamine Release [PE] | ||
|
CHEMBL224325
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
N0000184306
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
N0000171131
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
CHLORQUINALDOL
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
200-789-3
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
3095
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
SUB06211MIG
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
72-80-0
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
100000092132
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
74500
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
DB13306
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
DTXSID3048998
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
D6VHC87LLS
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
D6VHC87LLS
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
D002750
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY | |||
|
215
Created by
admin on Fri Dec 15 15:02:24 GMT 2023 , Edited by admin on Fri Dec 15 15:02:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY